366,553 Shares in Teleflex Incorporated $TFX Purchased by Capital International Investors

Key Points

• Capital International Investors acquired a new stake of 366,553 Teleflex (NYSE:TFX) shares valued at about $44.85 million, representing roughly 0.83% ownership, and institutional investors now hold about 95.62% of the stock.
• Teleflex reported a sizable quarterly miss — EPS $1.93 vs. $3.73 expected and revenue $569.0M vs. $912.6M expected — with revenue down 28.5% year‑over‑year and a negative net margin of 30.56%.
• The company set FY2026 guidance at $6.25–$6.55 EPS, declared a $0.34 quarterly dividend (1.3% yield), and Wall Street consensus is a "Hold" with an average price target of $140.83.

Capital International Investors acquired a new stake in shares of Teleflex Incorporated (NYSE:TFX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 366,553 shares of the medical technology company's stock, valued at approximately $44,851,000. Capital International Investors owned about 0.83% of Teleflex as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Norges Bank purchased a new stake in Teleflex in the 2nd quarter worth about $65,826,000. Thrivent Financial for Lutherans raised its position in Teleflex by 1,161.0% during the 3rd quarter. Thrivent Financial for Lutherans now owns 550,449 shares of the medical technology company's stock valued at $67,353,000 after purchasing an additional 506,796 shares in the last quarter. Qube Research & Technologies Ltd lifted its stake in Teleflex by 100.1% in the second quarter. Qube Research & Technologies Ltd now owns 606,804 shares of the medical technology company's stock worth $71,821,000 after acquiring an additional 303,521 shares during the period. Wedge Capital Management L L P NC purchased a new stake in shares of Teleflex in the 3rd quarter worth approximately $26,929,000. Finally, Boston Partners lifted its holdings in Teleflex by 112.5% during the second quarter. Boston Partners now owns 380,933 shares of the medical technology company's stock worth $45,085,000 after buying an additional 201,652 shares during the period. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Teleflex Stock Down 3.2%

Shares of TFX opened at $108.14 on Friday. The company's 50-day moving average price is $110.10 and its 200 day moving average price is $118.24. The company has a current ratio of 2.54, a quick ratio of 2.01 and a debt-to-equity ratio of 0.81. Teleflex Incorporated has a 12-month low of $100.18 and a 12-month high of $143.32. The firm has a market cap of $4.78 billion, a P/E ratio of -5.26, a price-to-earnings-growth ratio of 0.70 and a beta of 0.87.

Teleflex (NYSE:TFX - Get Free Report) last announced its earnings results on Thursday, February 26th. The medical technology company reported $1.93 EPS for the quarter, missing analysts' consensus estimates of $3.73 by ($1.80). Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. The firm had revenue of $569.00 million for the quarter, compared to analysts' expectations of $912.57 million. During the same quarter last year, the business earned $3.89 earnings per share. The business's revenue was down 28.5% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, sell-side analysts forecast that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th will be given a dividend of $0.34 per share. The ex-dividend date is Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.3%. Teleflex's payout ratio is -6.62%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TFX. Royal Bank Of Canada raised their target price on shares of Teleflex from $115.00 to $125.00 and gave the company a "sector perform" rating in a research note on Friday, February 27th. Weiss Ratings reissued a "sell (d)" rating on shares of Teleflex in a research report on Monday, December 29th. Needham & Company LLC boosted their price objective on Teleflex from $138.00 to $147.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Truist Financial increased their price target on shares of Teleflex from $120.00 to $135.00 and gave the stock a "hold" rating in a report on Thursday, December 18th. Finally, Wells Fargo & Company raised their price objective on Teleflex from $116.00 to $130.00 and gave the company an "equal weight" rating in a report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Teleflex currently has an average rating of "Hold" and an average price target of $140.83.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.